Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Gains from Sales and Divestitures (2024 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $282687.0 as the latest value for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 1155.61% year-over-year to $282687.0; the TTM value through Dec 2025 reached $282687.0, up 1155.61%, while the annual FY2025 figure was $282687.0, 1155.61% up from the prior year.
  • Gains from Sales and Divestitures hit $282687.0 in Q4 2025 for Artiva Biotherapeutics, up from $205360.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $282687.0 in Q4 2025 and bottomed at $22514.0 in Q4 2024.